期刊文献+

Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma 被引量:4

Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma
原文传递
导出
摘要 Esophagus squamous cell carcinoma(ESCC) is one of the most aggressive malignant tumors in the world. Our previous data demonstrates that oncoprotein MUC1 is related with metastasis and poor outcome of ESCC. However, alteration of MUC1 in ESCC remains unclear. Using ONCOMINE and COSMIC databases, we analyzed MUC1 gene copy numbers and gene mutations and found that MUC1 had high expression level but few gene mutations in ESCC. Further study of ESCC samples indicated that MUC1 O-glycosylation levels were higher in tumor tissues than that in para-carcinoma tissues in 10 of 14 pairs of ESCC samples. Moreover, we verified a potential link between MUC1 O-glycosylation and C1 GALT1, which was further supported by IHC analysis on 38 ESCC and 19 para-carcinoma samples. More importantly, co-expression of MUC1 Oglycosylation and C1 GALT1 presented positive correlations with both lymph node metastasis and survival time of ESCC patients. Our work collectively indicates that C1 GALT1 is associated with O-glycosylated MUC1 in ESCC, not only suggesting a diagnostic significance of C1 GALT1 and MUC1 O-glycosylation in ESCC, but also opening novel insights into targeting C1 GALT1 and MUC1 O-glycosylation to suppress ESCC cells metastasis in patients. Esophagus squamous cell carcinoma(ESCC) is one of the most aggressive malignant tumors in the world. Our previous data demonstrates that oncoprotein MUC1 is related with metastasis and poor outcome of ESCC. However, alteration of MUC1 in ESCC remains unclear. Using ONCOMINE and COSMIC databases, we analyzed MUC1 gene copy numbers and gene mutations and found that MUC1 had high expression level but few gene mutations in ESCC. Further study of ESCC samples indicated that MUC1 O-glycosylation levels were higher in tumor tissues than that in para-carcinoma tissues in 10 of 14 pairs of ESCC samples. Moreover, we verified a potential link between MUC1 O-glycosylation and C1 GALT1, which was further supported by IHC analysis on 38 ESCC and 19 para-carcinoma samples. More importantly, co-expression of MUC1 Oglycosylation and C1 GALT1 presented positive correlations with both lymph node metastasis and survival time of ESCC patients. Our work collectively indicates that C1 GALT1 is associated with O-glycosylated MUC1 in ESCC, not only suggesting a diagnostic significance of C1 GALT1 and MUC1 O-glycosylation in ESCC, but also opening novel insights into targeting C1 GALT1 and MUC1 O-glycosylation to suppress ESCC cells metastasis in patients.
出处 《Science China(Life Sciences)》 SCIE CAS CSCD 2018年第11期1389-1395,共7页 中国科学(生命科学英文版)
基金 supported by the National Natural Science Foundation of China (81472461)
关键词 MUC1 gene mutation GLYCOSYLATION CIGALT1 ESCC MUC1 gene mutation glycosylation CIGALT1 ESCC
分类号 Q [生物学]
  • 相关文献

参考文献1

二级参考文献58

  • 1Abken, H. (2015). Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy 7, 535-544.
  • 2Acres, B., Lacoste G., and Limacher J.M. (2015). Targeted immunotherapy designed to treat MUCl-expressing solid tumour. Curr Top Microbiol Immunol doi: 10.1007/82_2015_429.
  • 3Acres, B., and Limacher, J.M. (2005). MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4, 493-502.
  • 4Barnd, D.L., Lan, M.S., Metzgar, R.S., and Finn, O.J. (1989). Specific, major histocompatibility complex-unrestricted recognition of tu- mor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86, 7159-7163.
  • 5Barrett, D.M., Teachey, D.T., and Grupp S.A. (2014). Toxicity manage- ment for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26, 43-49.
  • 6Beatson, R., Maurstad G., Picco G., Arulappu A., Coleman J., Wandell, H. H., Clausen, H., Mandel, U., Taylor-Papadimitriou, J., Sletmoen, M., and Burchell J.M. (2015). The breast cancer-associated glycoforms of MUC1, MUCI-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL. PLoS One 10, e0125994.
  • 7Beatson, R.E., Taylor-Papadimitriou, J., and Burchell, J.M. (2010). MUC 1 immunotherapy. Immunotherapy 2, 305-327.
  • 8Blixt, O., Bueti, D., Burford, B., Allen, D., Julien, S., Hollingsworth, M., Gammerman, A., Fentiman, I., Taylor-Papadimitriou, J., and Burchell J. M. (2011). Autoantibodies to aberrantly glycosylated MUC 1 in early stage breast cancer are associated with a better prognosis. Breast Can- cer Res 13, R25.
  • 9Burchell, J., and Taylor-Papadimitriou, J. (1993). Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2, 155-162.
  • 10Chinnasamy, D., Yu, Z., Kerkar, S.P., Zhang, L., Morgan, R.A., Restifo, N.P., and Rosenberg, S.A. (2012). Local delivery of interleukin-12 us- ing T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18, 1672-1683.

共引文献18

同被引文献12

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部